Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Mature B-cell Malignancies: early-phase trial registry

1 of 2 indexed Mature B-cell Malignancies trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,203 of 28,963 conditions by registered trial count.

Jump to open trials → Trial finder

2 US clinical trials · 1 currently recruiting · #7,203 of 28,963 conditions by registered trial count

Mature B-cell Malignancies: 2 US clinical trials tracked, 1 recruiting.

Mature B-cell Malignancies is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is InnoCare Pharma, running 1 of these trials.

Enrollment posture brief

Registry condition mature-b-cell-malignancies

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7203 | SPON 1

Volume-matched condition peers

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Mature B-cell Malignanci (th…50%
Open-enrollment share among volume-matched conditions near Mature B-cell Malignancies

Mature B-cell Malignancies lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mature B-cell Malignancies on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Mature B-cell Malignancies is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

InnoCare Pharma 1 trials
BeiGene 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Compare conditions side-by-side

Read our methodology - how this data is sourced, computed, and verified.

Research context

Helpful clinical-trial guides

This page summarizes registry records, not medical advice or a recommendation to join a study. These guides explain how to interpret the information shown here and what to verify with a study team.

How clinical trials workUnderstand study records, eligibility, and study status. Finding a trialLearn the questions to take to a study contact or clinician. Informed consentReview what consent does and does not mean for participants.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.